Pharmacist Loses Legal Fight Over Bulk Drug Compounding

German Court Bans Bulk Production of Compounded Medications by Pharmacists

A pharmacist from Kiel has lost a legal battle over the production of compounded medications for general practice use. The Federal Administrative Court upheld a ban on manufacturing and distributing such drugs in bulk. The ruling clarifies strict limits on how pharmacies can prepare and supply medications outside individual prescriptions.

The case centred on a Kiel-based pharmacist who produced large quantities of fluorescein injection solutions and bowel lavage powders. These were supplied to doctors without being tied to specific patient prescriptions. The Schleswig-Holstein State Office for Occupational Safety, Social Affairs, and Health had previously prohibited this practice, arguing it violated regulations under the Medicines Act (AMG), Pharmacy Operating Regulations (ApBetrO), and the Medicines Prescription Ordinance (AMVV).

The pharmacist initially won an appeal at the Higher Administrative Court, which overturned the ban. However, the Federal Administrative Court later reversed that decision, siding with the authorities. It ruled that producing ready-made drugs for an indefinite number of patients—rather than for individual cases—amounted to commercial-scale manufacturing, not compounding. EU directives state that compounding must be prescription-based and tailored to specific patients. The court emphasised that bulk production, even under practice stock rules, risks undermining patient safety standards. While some European countries, such as France, the Netherlands, and Belgium, allow national exceptions for locally compounded drugs, German law remains stricter. The exemption for compounded medications aims to balance safety with supply needs. Yet the court found that large-scale preparation without individual prescriptions conflicts with EU and German regulations.

The ruling reinforces that pharmacies cannot mass-produce compounded drugs for general use. Instead, such medications must be prepared only under specific prescriptions. The decision may pose supply challenges but aligns with EU-wide standards on patient safety and manufacturing controls.